- Trial phase
- Preclinical
- Time to market
- At least 5-7 years, assuming successful CTA filing in Q4 2026, Phase 1 initiation in 2027, and multiple subsequent clinical trial phases before potential approval.
- Why 4/10
- The next hard, dated catalyst is the Clinical Trial Application (CTA) filing expected in Q4 2026 (by end of December 2026, ~2 months away). This is a regulatory milestone that transitions the program from preclinical to clinical, but it is not a binary data readout or approval decision. WVE-008 is one of several pipeline programs at Wave (alongside WVE-006, WVE-007, WVE-N531, WVE-003), so it is not the sole value driver. ImpactScore of 4 reflects a preclinical-stage drug with a near-term non-data catalyst at a company with multiple other programs.
The next catalyst for WVE-008 is the CTA filing expected in Q4 2026 (by end of December 2026). A successful filing would transition the program from preclinical to clinical development and validate Wave's RNA editing platform in a second indication after WVE-006. Investors should watch for the actual filing announcement and any details on the planned Phase 1 trial design. The stock also has other near-term catalysts including WVE-006's regulatory pathway and WVE-007 obesity data.
Price Chart
Executive Summary
WVE-008 is an investigational RNA editing therapy (AIMer) from Wave Life Sciences (Nasdaq: WVE) targeting PNPLA3 I148M liver disease, a genetic form of fatty liver disease affecting an estimated ~9 million homozygous patients in the U.S. and Europe. The drug is still preclinical, no clinical trials have started. As of Wave's Q3 2026 earnings report today (Oct 27, 2026), the company stated that a Clinical Trial Application (CTA) filing is on track for Q4 2026, which would be the next catalyst. WVE-008 is one of several pipeline programs at Wave, alongside obesity candidate WVE-007 (Phase 2), AATD candidate WVE-006 (Phase 1/2 with FDA alignment on registrational pathway), and DMD/Huntington's programs. The stock trades near its 52-week low (~$3.21) with a strong analyst consensus (20 Buy/Strong Buy ratings, mean target $17.68) but faces competition from J&J's PNPLA3 siRNA program that has already generated Phase 1 data.
How It Works
WVE-008 is an RNA-editing drug designed to correct a specific genetic typo (the PNPLA3 I148M mutation) that is the strongest known genetic risk factor for fatty liver disease. It works like a molecular 'find-and-replace' tool: a short, chemically modified piece of RNA (called an AIMer) is delivered to liver cells via a GalNAc sugar molecule that targets the liver. Once inside, it recruits a naturally occurring enzyme (ADAR) to edit the faulty RNA message, restoring production of the normal PNPLA3 protein. This is different from gene silencing (which destroys the RNA), RNA editing fixes the message while keeping the cell's natural regulation intact.
Trial Status
WVE-008 is in preclinical development. A clinical candidate was selected and announced in October 2025. Preclinical data presented at AASLD 2025 showed that PNPLA3 AIMers achieved substantial editing of the PNPLA3 I148M transcript in primary human hepatocytes, exceeding the ~50% threshold expected to lower liver disease risk. The company expects to file a Clinical Trial Application (CTA) in Q4 2026 to begin first-in-human studies.
The Two-Sided Case
Upcoming Catalysts
- CTA filing for WVE-008 expected in Q4 2026 (by end of December 2026)
- Potential Phase 1 trial initiation in 2027 following CTA/IND clearance
- Preclinical data updates at medical conferences (e.g., AASLD, EASL)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Wave Life Sciences USA, Inc. PRESS-RELEASE WVE ·Originating report